Fig. 5From: Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemiaPhase 3 trial of idelalisib + rituximab versus rituximab monotherapy in patients with relapsed CLL and clinically significant coexisting medical conditions [62]. a Progression-free survival. b Overall survival. CLL chronic lymphocytic leukemia. Reproduced with permission from [62]Back to article page